Intro

This chapter reviews findings from the ACR Convergence 2024 regarding the comparative risks of tofacitinib and adalumab for rheumatoid arthritis treatment. It emphasizes the significance of statin use and optimizing baseline therapy to manage associated cardiovascular risks.